Cardiff Oncology, Inc. (TROV) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Royalty						0.3	0.3	0.3
Diagnostic services							0.1	0.0
Services						0.2
Other							0.0	0.0
Total revenues [+]	0.4	0.4	0.4	0.2	0.4	0.5	0.4	0.3
Royalties						0.3	0.3	0.3
Services						0.2	0.1	0.0
Other							0.0	0.0
Revenue growth [+]	7.5%	-1.9%	49.6%	-35.3%	-25.1%	32.6%	21.8%	11.6%
Royalty						10.6%	-6.0%	1.7%
Diagnostic services							524.7%
Cost of goods sold	0.0	0.0	0.0	-16.9	0.6	1.8	1.7	0.6
Gross profit	0.4	0.4	0.4	17.2	-0.2	-1.3	-1.3	-0.3
Gross margin	100.0%	100.0%	100.0%	7018.6%	-57.9%	-258.4%	-354.1%	-101.1%
Selling, general and administrative [+]	13.2	11.8	8.2	5.8	8.0	14.2	23.0	14.4
Sales and marketing							11.5	6.4
General and administrative							11.5	7.9
Research and development	27.1	17.4	11.2	11.2	8.2	7.9	15.0	10.6
Other operating expenses				16.9
EBITDA [+]	-39.7	-28.4	-18.6	-16.2	-15.5	-22.2	-38.3	-24.9
EBITDA growth	39.6%	52.5%	15.1%	4.2%	-30.0%	-42.1%	53.8%	69.2%
EBITDA margin	-10276.2%	-7912.0%	-5087.4%	-6615.8%	-4104.7%	-4387.4%	-10046.8%	-7958.4%
Depreciation and amortization	0.2	0.5	0.5	0.5	0.9	1.2	1.1	0.4
EBIT [+]	-39.9	-28.9	-19.1	-16.7	-16.4	-23.4	-39.4	-25.3
EBIT growth	38.3%	51.2%	14.4%	1.8%	-30.0%	-40.5%	55.7%	69.1%
EBIT margin	-10337.3%	-8037.6%	-5214.8%	-6817.8%	-4331.9%	-4634.2%	-10327.5%	-8079.5%
Non-recurring items					0.7	2.2	0.8
Interest expense, net [+]	-1.6	-0.3	-0.1	-0.2	-0.2	0.9	1.4	1.5
Interest expense			0.0		0.0	1.0	1.7	1.5
Interest income	1.6	0.3	0.1	0.2	0.2	0.1	0.3
Other income (expense), net [+]	-0.4	0.3	-0.3	0.0	0.4	1.6	2.3	-0.7
Gain (loss) on debt retirement					0.0	-1.7
Unrealized gain/loss on derivatives		0.3	-0.3	0.0	0.6	3.4	2.5	-0.7
Other non-operating gains/losses	-0.4	0.0	0.0
Other	-0.4	0.0	0.0
Pre-tax income	-38.7	-28.3	-19.3	-16.4	-16.5	-24.9	-39.2	-27.5
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-38.7	-28.3	-22.6	-16.7	-19.3	-24.9	-39.2	-27.5
Net margin	-10033.2%	-7887.2%	-6174.3%	-6829.3%	-5089.5%	-4932.9%	-10294.1%	-8789.7%

Basic EPS [+]	($0.89)	($0.73)	($1.08)	($2.80)	($8.26)	($51.76)	($1.30)	($1.05)
Growth	22.4%	-33.0%	-61.3%	-66.2%	-84.0%	3881.4%	23.9%	38.3%
Diluted EPS [+]	($0.89)	($0.73)	($1.08)	($2.80)	($8.26)	($51.76)	($1.30)	($1.04)
Growth	22.4%	-33.0%	-61.3%	-66.2%	-84.0%	3895.5%	24.6%	38.2%

Shares outstanding (basic) [+]	43.6	39.0	20.9	6.0	2.3	0.5	30.2	26.2
Growth	11.7%	87.0%	249.4%	156.4%	383.8%	-98.4%	15.2%	38.6%
Shares outstanding (diluted) [+]	43.6	39.0	20.9	6.0	2.3	0.5	30.3	26.5
Growth	11.7%	87.0%	249.4%	156.4%	383.8%	-98.4%	14.5%	38.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.